| Literature DB >> 26358792 |
Michael B Streiff1, Bjorn Holmstrom1, Aneel Ashrani1, Paula L Bockenstedt1, Carolyn Chesney1, Charles Eby1, John Fanikos1, Randolph B Fenninger1, Annemarie E Fogerty1, Shuwei Gao1, Samuel Z Goldhaber1, Paul Hendrie1, Nicole Kuderer1, Alfred Lee1, Jason T Lee1, Mirjana Lovrincevic1, Michael M Millenson1, Anne T Neff1, Thomas L Ortel1, Rita Paschal1, Sanford Shattil1, Tanya Siddiqi1, Kristi J Smock1, Gerald Soff1, Tzu-Fei Wang1, Gary C Yee1, Anaadriana Zakarija1, Nicole McMillian1, Anita M Engh1.
Abstract
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26358792 DOI： 10.6004/jnccn.2015.0133
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908